Donate Today for a Chance to Win this 2025 Corvette ZR1 Coupe with the ZTK Performance Package!
You’ve got a chance to win a 2025 ZR1 Corvette Coupe with the ZTK Performance Package in stunning Sebring Orange!
Chevrolet has unleashed the unthinkable in the Corvette ZR1. The King of the Hill returns with the most powerful V8 ever produced in America from an auto manufacturer, mind-bending specs and iconic design to challenge the world’s best supercars in both coupe and convertible variants.
Corvette ZR1 features a 5.5L, twin-turbocharged DOHC flat-plane crank V8 engine dubbed the LT7. The LT7 engine produces 1,064 horsepower at 7,000 rpm and 828 lb-ft of torque at 6,000 rpm, per SAE guidelines — the most power ever from a factory Corvette and the most powerful V8 ever produced in America from an auto manufacturer.
Corvette ZR1 boasts a GM-determined top speed of 233 mph on the racetrack and will dispatch the quarter mile with a GM-estimated sub-10-second time. The purposeful carbon fiber aero package creates over 1,200 pounds of downforce at top speed. And the ZR1 coupe revives one of the most iconic styles in Corvette history: the split rear window.
"There is an insatiable thirst in the sports car world for the ultimate in performance. And the ZR1 is certainly that in the Corvette lineup. It's at the very top."
Josh Holder, Corvette Chief Engineer
We can’t forget Chip Miller’s tremendous personal Corvette collection and creation of the grandest Corvette event anywhere on the planet – Corvettes at Carlisle. Chip and his close friend Bill Miller founded the incredibly successful automotive event production company, Carlisle Events, held at the Carlisle Fairgrounds in Pennsylvania.
In December 2003, Chip was diagnosed with a little-known disease called Amyloidosis. Sadly, due to complications from the disease, the world lost an incredibly special human being on March 25, 2004. Had Chip and his doctors been aware of the symptoms of the disease when they first presented, this legend might still be with us today.
Amyloidoses are rare diseases first described over 200 years ago. The disease manifests itself when amyloid proteins deposit and accumulate in the body’s organs and tissue. This accumulation may happen systemically (throughout the body) or locally (in one tissue).
Each year 3,000 cases of Amyloidosis are diagnosed in the United States. Amyloidosis is generally a disease of middle-aged people and older, although the disease has been seen in individuals in their thirties. Men are more likely to be affected than women by a ratio of about 1.5:1. Other diseases can increase the risk of Amyloidosis and family history of the disease may indicate a hereditary version. 10-15% of people with multiple myeloma develop Amyloidosis. Long-term kidney dialysis may increase the risk of dialysis-associated Amyloidosis.